RecruitingPhase 2NCT06057935
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Studying Malignant peritoneal mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Garrett Nash, MDMemorial Sloan Kettering Cancer
- Intervention
- Pemetrexed(drug)
- Enrollment
- 64 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (13)
- University of Chicago (Data Collection Only), Chicago, Illinois, United States
- University of Michigan (Data Collection Only), Ann Arbor, Michigan, United States
- Washington University (Data Collection Only), St Louis, Missouri, United States
- University of Nebraska (Data collection only), Omaha, Nebraska, United States
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Rutgers University (Data Collection Only), New Brunswick, New Jersey, United States
- Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activites), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
- Allegheny Health Network (Data Collection Only), Pittsburgh, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06057935 on ClinicalTrials.govOther trials for Malignant peritoneal mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07330271PTC-Guided Therapy for Peritoneal MesotheliomaBeijing Tsinghua Chang Gung Hospital
- RECRUITINGPHASE2NCT06543069Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGNCT06581549Immune Microenvironment and Gene Expression Profiling in MesotheliomaIstituto Oncologico Veneto IRCCS